Find the right fit for you - faster
Get tailored insights about working at Adimab in one quick step.
Adimab Snapshot
We are the leading provider for therapeutics antibody discovery and engineering technologies, focusing solely on our partners without pursuing an internal product pipeline. Since 2009, we have partnered with over 95 pharmaceutical and biotechnology companies, generating more than 425 therapeutic programs, of which more than 55 have entered clinical trials. Our technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.
Our integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. We offer fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Our integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. We offer fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
